Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort

Basit Öğe Kaydı
dc.contributor.authorIdilman, Ramazan
dc.contributor.authorDemir, Mehmet
dc.contributor.authorAladag, Murat
dc.contributor.authorErol, Cihan
dc.contributor.authorCavus, Bilger
dc.contributor.authorIliaz, Raim
dc.contributor.authorKoklu, Hayrettin
dc.date.accessioned2024-02-23T14:24:32Z
dc.date.available2024-02-23T14:24:32Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractThe aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC. Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma.en_US
dc.identifier.doi10.1111/jvh.13075
dc.identifier.endpage674en_US
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.issue6en_US
dc.identifier.pmid30740820en_US
dc.identifier.scopus2-s2.0-85062685356en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage666en_US
dc.identifier.urihttps://doi.org/10.1111/jvh.13075
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13993
dc.identifier.volume26en_US
dc.identifier.wosWOS:000469027000006en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal Of Viral Hepatitisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCirrhosisen_US
dc.subjectDirect-Acting Antiviralsen_US
dc.subjectHepatitis C Virusen_US
dc.subjectHepatocellular Carcinomaen_US
dc.subjectLiver Transplantationen_US
dc.titleLow recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohorten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu